CurrentBlue Cross Blue Shield - IllinoisPolicy CPCPLABO49

General Inflammation Testing

Defines Blue Cross Blue Shield Illinois reimbursement and testing frequency preferences for measurement of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) for specific diagnosed or suspected inflammatory conditions and general inflammation testing rules affecting providers submitting lab claims.

Policy Summary

PayerBlue Cross Blue Shield - Illinois

PolicyGeneral Inflammation Testing

Policy CodePolicy CPCPLABO49

Change TypeNew policy (effective Jan 1, 2026)

Effective DateJan 1, 2026

Next Review Date

Key ActionSubmit accurate documentation and use valid HIPAA-approved code sets; BCBSIL may request additional documentation.

SourceLink

POLICY UPDATE CHANGES

New policy implemented establishing coverage and preferred use of CRP and/or ESR for specified conditions and testing frequencies.

Table of conditionsConditions listed

CRP preferredPreferred biomarker

Not reimbursableUndiagnosed exclusion

Not reimbursableRoutine exam exclusion

2026-01-01

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Condition-specific Coverage

Condition-specific coverage criteria (selected examples)

CRP and/or ESR may be reimbursable for specific diagnosed or suspected inflammatory conditions with preference and frequency guidance outlined below.

ALL of the following

ALL of the following
- Test preference: CRP
- Frequency: To confirm diagnosis; every 2-3 days during the early therapeutic course; weekly until normalization or a clear trend toward normalization is evident

ALL of the following

ALL of the following
- Test preference: CRP
- Frequency: Not specified

ALL of the following

ALL of the following
- Test preference: CRP or ESR
- Frequency: Not specified

ALL of the following

ALL of the following
- Test preference: CRP or ESR
- Frequency: Regular interval use in patients with active symptoms

ALL of the following

ALL of the following
- Test preference: CRP or ESR
- Frequency: 1-3 months initially; 6-12 months later (then not specified)

ALL of the following

ALL of the following
- Test preference: CRP
- Frequency: 1-3 months initially; 6-12 months later

ALL of the following

ALL of the following
- Test preference: ESR
- Frequency: 1-3 months initially; every 3-6 months for up to 2 years; every 6-12 months for the next 3 years; annually thereafter

ALL of the following

ALL of the following
- Test preference: CRP and ESR
- Frequency: During initial assessment to exclude other diagnoses (e.g., inflammatory bowel disease)

ALL of the following

ALL of the following
- Test preference: CRP and ESR
- Frequency: To confirm diagnosis; every 1-3 months during the first year; every 3-6 months thereafter

ALL of the following

ALL of the following
- Test preference: CRP or ESR
- Frequency: Regular interval use in patients with active symptoms

ALL of the following

ALL of the following
- Test preference: CRP or ESR
- Frequency: At initial diagnosis; every 3 months during long-term steroid therapy

ALL of the following

ALL of the following
- Test preference: CRP and ESR
- Frequency: Not specified

ALL of the following

ALL of the following
- Test preference: CRP or ESR
- Frequency: Prior to treatment; every 1-3 months during active disease; annually when disease is inactive

ALL of the following

ALL of the following
- Test preference: CRP or ESR
- Frequency: At initial assessment; every 1-3 months during active disease; every 6-12 months during stable disease; during pregnancy

ALL of the following

ALL of the following
- Test preference: ESR
- Frequency: Not specified

Procedure Codes & Frequency Guidance

Procedure codes guidancemixed

Procedure codes list is not all-encompassing; inclusion does not guarantee coverage.

Frequency guidance examples — monitoring intervals per condition

Rheumatoid arthritis monitoringPrior to treatment; every 1–3 months during active disease; annually when disease is inactive.

Acute hematogenous osteomyelitis (AHO) / Acute infection monitoringTo confirm diagnosis; every 2–3 days early in therapy; weekly until normalization or clear trend.

Large vessel vasculitis (Giant cell arteritis, Takayasu)To confirm diagnosis; every 1–3 months during the first year; every 3–6 months thereafter.

Polymyalgia rheumaticaAt initial diagnosis; every 3 months during long-term steroid therapy.

Systemic lupus erythematosus (SLE)At initial assessment; every 1–3 months during active disease; every 6–12 months when stable; during pregnancy.

Documentation, Ordering & Claims Submission

Documentation Required

Documentation and claims submission required; BCBSIL may request additional documentation

Providers must submit accurate documentation of services performed and submit claims using valid HIPAA‑approved code sets. BCBSIL may request additional documentation and retains discretion in interpreting and applying this policy.

Submit claims using valid code combinations from HIPAA‑approved code sets (e.g., CPT, HCPCS, ICD‑10).
Code claims according to industry standard coding guidelines (Uniform Billing Editor, AMA CPT, CMS NCCI, etc.).
Upon request, provide any additional documentation to support the claim.

Billing Rule

Ordering restrictions: CRP preferred when both ordered; testing limited to listed conditions

Biomarker Preferences & Reimbursement Exclusions

CRP preference and acceptable methods

Preferred biomarker when either allowedWhen either CRP or ESR are allowed, CRP is the preferred biomarker.

CRP methods acceptedBoth conventional CRP and high-sensitivity CRP (hs-CRP) testing methods are acceptable.

Concurrent orders policyIf CRP and ESR are ordered at the same time for a condition where CRP or ESR are allowed, only CRP will be allowed.

ESR reimbursement limitationMeasurement of ESR for individuals without a diagnosed inflammatory condition is not reimbursable.

Routine exam exclusionMeasurement of CRP and/or ESR during a general exam without abnormal findings is not reimbursable.

Exclusions — ESR and routine exam testing